$2.47T
Total marketcap
$201.59B
Total volume
BTC 50.21%     ETH 15.64%
Dominance

BridgeBio Pharma BBIO Stock

27.81 USD {{ price }} 0.907112% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
5.13B USD
LOW - HIGH [24H]
27.22 - 28.57 USD
VOLUME [24H]
1.97M USD
{{ volume }}
P/E Ratio
0
Earnings per share
-3.95 USD

BridgeBio Pharma Price Chart

BridgeBio Pharma BBIO Financial and Trading Overview

BridgeBio Pharma stock price 27.81 USD
Previous Close 16.89 USD
Open 16.6 USD
Bid 0 USD x 1200
Ask 0 USD x 800
Day's Range 15.22 - 16.64 USD
52 Week Range 6.55 - 19.95 USD
Volume 2.02M USD
Avg. Volume 2.18M USD
Market Cap 2.49B USD
Beta (5Y Monthly) 0.706023
PE Ratio (TTM) N/A
EPS (TTM) -3.95 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 28.56 USD

BBIO Valuation Measures

Enterprise Value 3.74B USD
Trailing P/E N/A
Forward P/E -6.1343875
PEG Ratio (5 yr expected) 0.09
Price/Sales (ttm) 32.025913
Price/Book (mrq) N/A
Enterprise Value/Revenue 48.092
Enterprise Value/EBITDA -8.625

Trading Information

BridgeBio Pharma Stock Price History

Beta (5Y Monthly) 0.706023
52-Week Change 102.87%
S&P500 52-Week Change 20.43%
52 Week High 19.95 USD
52 Week Low 6.55 USD
50-Day Moving Average 14.73 USD
200-Day Moving Average 11.71 USD

BBIO Share Statistics

Avg. Volume (3 month) 2.18M USD
Avg. Daily Volume (10-Days) 1.58M USD
Shares Outstanding 160.5M
Float 93.11M
Short Ratio 8.39
% Held by Insiders 5.74%
% Held by Institutions 90.98%
Shares Short 13.51M
Short % of Float 14.49%
Short % of Shares Outstanding 8.41%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) -565.97%
Gross Margin 96.48%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -38.24%
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) 77.78M USD
Revenue Per Share (ttm) 0.52 USD
Quarterly Revenue Growth (yoy) 7.79%
Gross Profit (ttm) 74.21M USD
EBITDA -433695008 USD
Net Income Avi to Common (ttm) -424942016 USD
Diluted EPS (ttm) -2.62
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 491.29M USD
Total Cash Per Share (mrq) 3.06 USD
Total Debt (mrq) 1.73B USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 5.722
Book Value Per Share (mrq) -7.64

Cash Flow Statement

Operating Cash Flow (ttm) -403180992 USD
Levered Free Cash Flow (ttm) -253781744 USD

Profile of BridgeBio Pharma

Country United States
State CA
City Palo Alto
Address 3160 Porter Drive
ZIP 94304
Phone 650 391 9740
Website https://www.bridgebio.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 392

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Q&A For BridgeBio Pharma Stock

What is a current BBIO stock price?

BridgeBio Pharma BBIO stock price today per share is 27.81 USD.

How to purchase BridgeBio Pharma stock?

You can buy BBIO shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for BridgeBio Pharma?

The stock symbol or ticker of BridgeBio Pharma is BBIO.

Which industry does the BridgeBio Pharma company belong to?

The BridgeBio Pharma industry is Biotechnology.

How many shares does BridgeBio Pharma have in circulation?

The max supply of BridgeBio Pharma shares is 184.45M.

What is BridgeBio Pharma Price to Earnings Ratio (PE Ratio)?

BridgeBio Pharma PE Ratio is now.

What was BridgeBio Pharma earnings per share over the trailing 12 months (TTM)?

BridgeBio Pharma EPS is -3.95 USD over the trailing 12 months.

Which sector does the BridgeBio Pharma company belong to?

The BridgeBio Pharma sector is Healthcare.

BridgeBio Pharma BBIO included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
Nasdaq US 700 Small Cap Index NQUS700SC 2078.81 USD
-0.4
2075.76 USD 2093.28 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD